RxSight(US:RXST) Globenewswire·2025-10-08 23:10Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against RxSight, Inc. following a class action lawsuit that alleges the company made false statements and failed to disclose significant issues affecting its sales and financial guidance [1][6]. Summary by Sections Company Overview - RxSight, Inc. is facing a class action lawsuit filed on July 22, 2025, with a class period from November 7, 2024, to July 8, 2025, concerning alleged breaches of fiduciary duties by its board of directors [1]. Allegations - The lawsuit claims that RxSight experienced "adoption challenges" and structural issues leading to declines in sales and utilization of its products [6]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [6]. Financial Impact - On July 8, 2025, RxSight reported preliminary second-quarter financial results showing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [6]. - The company lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint, and the CEO attributed the sales stall to adoption challenges [6]. - Following this announcement, RxSight's stock price fell nearly 38% [6].